This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT

Start Date27 Sep 2023

Sponsor / Collaborator

Stanford University

NCT05622162 / Active, not recruitingPhase 3

Phase III Multicentre Prospective Comparative Study of Detection Rate of 18F-JK-PSMA-7 and of 18F-fluorocholine in Patients With Biochemical Recurrence of Prostate Cancer After Previous Treatment With Curative Intent

The present study in patients with Prostate cancer and biochemical failure after surgery and/or radical-postoperative Radio Therapy (RT) will evaluate if PET/CT with 18F-JK-PSMA-7 compared to PET-CT 18F-Choline is able to identify the early pattern of biochemical recurrence and/or metastatic sites, so that the patient could be better managed, with a benefit in survival.

Start Date19 Dec 2022

Sponsor / Collaborator

ITEL Telecomunicazioni SRL

NCT04965454 / RecruitingPhase 2IIT

Clinical Trial of Biomarkers for Predicting Immunotherapy Response in Hepatocellular Carcinoma

This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable hepatocellular carcinoma (HCC). The primary objective of this diagnostic trial is to assess the accuracy of pre-treatment fluorine-18 (18F-) fluorocholine (FCH) PET/CT for predicting a lack of objective response (LOR) after 16 weeks of ICI therapy.

Start Date28 Mar 2022

Sponsor / Collaborator

The Queen's Medical Center

[+1]

100 Clinical Results associated with 18F-Fluorocholine

100 Translational Medicine associated with 18F-Fluorocholine

100 Patents (Medical) associated with 18F-Fluorocholine

288

Literatures (Medical) associated with 18F-Fluorocholine

01 Mar 2024·Indian Journal of Nuclear Medicine

Fluorine-18 FDG PET/CT and New NIMS Grading System for Chemotherapy Response in Breast Cancer

Article

Author: Srivastava, Madhur Kumar ; Vakati, Geethika Reddy ; Ratnagiri, Ranganath

AbstractBackground:Positron emission tomography with computed tomography (PET-CT) using fluorine 18-fluorodeoxyglucose (F-18 FDG) is increasingly used to stage patients with locally advanced breast cancer and for assessing treatment response after neoadjuvant chemotherapy (NACT).Aims and Objectives:The aim of the study was to assess the correlation between PET-CT parameters and pathologic response of breast primary after NACT in breast cancer patients and to devise a grading system called NIMS grading system for response assessment using PET quantitative parameters.Materials and Methods:55 patients who underwent F-18 FDG PET-CT before starting the therapy and again after completion of therapy were identified and included in the study. The clinical data and the histopathologic findings were recorded. All the patients received chemotherapy followed by surgery with axillary lymph node dissection. The PET-CT results were interpreted both qualitatively by visual analysis and quantitatively by estimating maximum Standardized uptake values(SUVmax) and other parameters – SUVmean, SUL, SUVBSA, Metabolic tumor volume (MTV) and Total lesion glycolysis (TLG).Results:The sensitivity and specificity of F-18 FDG PET-CT to detect the residual disease after neoadjuvant chemotherapy was 75.6% & 92.8% respectively. Differences between complete response and residual disease were significant for ΔSUVmax(p=0.005), ΔSUVmean(p=0.006), ΔSUL (0.005) and ΔSUVBSA(0.004), while ΔMTV and ΔTLG were not significantly different between the two groups. The new NIMS grading system included scoring of ΔSUVmax, ΔSUVBSA, ΔTLG and ΔMTV on scale of 1 to 4 and correlated well with PERCIST criteria.Conclusion:F-18 FDG PET-CT had a good accuracy in the detection of residual disease after completion of NACT. Pre chemotherapy PET-CT is not adequate to predict the response of primary tumour to chemotherapy. However, changes in the values of various PET-CT parameters are a sensitive tool to assess the response to chemotherapy. The new grading system is easy to use and showed good correlation to PERCIST.

01 Mar 2024·Radiology: Imaging Cancer

Breast Cancer Detection Using a Low-Dose Positron Emission Digital Mammography System

Article

Author: Olsen, Kenneth O ; Freitas, Vivianne ; Ghai, Sandeep ; Parker, Shayna ; Baldassi, Brandon ; Kulkarni, Supriya ; Li, Xuan ; Scaranelo, Anabel ; Reznik, Alla ; Komarov, Borys ; Bubon, Oleksandr ; Taeb, Samira ; Macsemchuk, Craig A ; Waterston, Michael ; Au, Frederick

Purpose To investigate the feasibility of low-dose positron emission mammography (PEM) concurrently to MRI to identify breast cancer and determine its local extent. Materials and Methods In this research ethics board-approved prospective study, participants newly diagnosed with breast cancer with concurrent breast MRI acquisitions were assigned independently of breast density, tumor size, and histopathologic cancer subtype to undergo low-dose PEM with up to 185 MBq of fluorine 18-labeled fluorodeoxyglucose (¹⁸F-FDG). Two breast radiologists, unaware of the cancer location, reviewed PEM images taken 1 and 4 hours following ¹⁸F-FDG injection. Findings were correlated with histopathologic results. Detection accuracy and participant details were examined using logistic regression and summary statistics, and a comparative analysis assessed the efficacy of PEM and MRI additional lesions detection (ClinicalTrials.gov: NCT03520218). Results Twenty-five female participants (median age, 52 years; range, 32-85 years) comprised the cohort. Twenty-four of 25 (96%) cancers (19 invasive cancers and five in situ diseases) were identified with PEM from 100 sets of bilateral images, showcasing comparable performance even after 3 hours of radiotracer uptake. The median invasive cancer size was 31 mm (range, 10-120). Three additional in situ grade 2 lesions were missed at PEM. While not significant, PEM detected fewer false-positive additional lesions compared with MRI (one of six [16%] vs eight of 13 [62%]; P = .14). Conclusion This study suggests the feasibility of a low-dose PEM system in helping to detect invasive breast cancer. Though large-scale clinical trials are essential to confirm these preliminary results, this study underscores the potential of this low-dose PEM system as a promising imaging tool in breast cancer diagnosis. ClinicalTrials.gov registration no. NCT03520218 Keywords: Positron Emission Digital Mammography, Invasive Breast Cancer, Oncology, MRI Supplemental material is available for this article. © RSNA, 2024 See also commentary by Barreto and Rapelyea in this issue.

01 Mar 2024·Current Pharmaceutical Design

Challenging Axillary Lymph Nodes on PET/CT in Cancer Patients throughout COVID-19 Vaccination Era

Article

Author: Gallicchio, Rosj ; Storto, Rebecca ; Giordano, Alessia ; Di Cosola, Michele ; Storto, Giovanni ; Milella, Mariarita ; Pellegrino, Teresa ; Nappi, Antonio ; Nardelli, Anna

Background:The unexpected detection of axillary lymphadenopathy (AxL) in cancer patients (pts) represents a real concern during the COVID-19 vaccination era. Benign reactions may take place after vaccine inoculation, which can mislead image interpretation in patients undergoing F-18-FDG, F-18-Choline, and Ga-68-DOTATOC PET/CT. They may also mimic loco-regional metastases or disease. We assessed PET/CT findings after COVID-19 first dose vaccination in cancer patients and the impact on their disease course management.Methods:We evaluated 333 patients undergoing PET/CT (257 F-18-FDG, 54 F-18-Choline, and 23 Ga-68 DOTATOC) scans after the first vaccination with mRNA vaccine (Pfizer-BioNTech) (study group; SG). The uptake index (SUVmax) of suspected AxL was defined as significant when the ratio was > 1.5 as compared to the contralateral lymph nodes. Besides, co-registered CT (Co-CT) features of target lymph nodes were evaluated. Nodes with aggregate imaging positivity were further investigated.Results:Overall, the prevalence of apparently positive lymph nodes on PET scans was 17.1% during the vaccination period. 107 pts of the same setting, who had undergone PET/CT before the COVID-19 pandemic, represented the control group (CG). Only 3 patients of CG showed reactive lymph nodes with a prevalence of 2.8% (p < 0.001 as compared to the vaccination period). 84.2% of SG patients exhibited benign characteristics on co-CT images and only 9 pts needed thorough appraisal.Conclusion:The correct interpretation of images is crucial to avoid unnecessary treatments and invasive procedures in vaccinated cancer pts. A detailed anamnestic interview and the analysis of lymph nodes’ CT characteristics, after performing PET/CT, may help to clear any misleading diagnosis.

News (Medical) associated with 18F-Fluorocholine

22 May 2023

·www.sciencedaily.com

Fluorine-based new drug synthesis at lightning speed

Researchers synthesize fluorine-based compound via rapid biphasic (gas and liquid) mixing. How short is one second? The duration of a second can be defined as one 86,400th of a 24-hour day. A bullet train traveling at 300 km per hour can cover a distance of 83 meters in one second. On average, an individual's blink lasts for 0.3 seconds, allowing for three blinks to occur within one second. A joint team of researchers from POSTECH has proposed a synthesis method for fluorine-based compound via a rapid mixing reaction between a gaseous component and liquid that takes less than a single second. The research team led by Professor Dong-Pyo Kim and Jeong-Un Joo (Department of Chemical Engineering at POSTECH), and Professor Heejin Kim and Hyune-Jea Lee (currently, a researcher at Samsung Advanced Institute of Technology) from the Department of Chemistry at Korea University has successfully developed a new method for synthesizing trifluoromethyl intermediate (-CF3) from fluoroform (CHF3). It involves the use of a special reactor capable of achieving an ultra-fast mixing between gas and liquid. This method offers promising prospects for the synthesis of novel fluorine-based new drugs. The research was published in Nature Communications. Fluorine is not found in its pure form naturally, but instead exists solely in the form of various chemical compounds. Sodium fluoride, a compound containing fluorine, is used as an ingredient in toothpaste due to its ability to coat teeth and prevent cavities. Recent studies have highlighted the potential of synthetic drug molecules containing fluorine as they possess high permeability into cell membranes of diseased tissues and exhibit strong binding affinity against proteins. Consequently, there is growing interest in the development of drugs containing fluorine. There are several approaches to synthesizing trifluoromethyl, but the most cost-effective method involves substituting a hydrogen atom from fluoroform, a simple precursor, with another element or functional group. However, gaseous fluoroform is volatile, which makes it difficult to mix with liquids and exhibits low reactivity. Moreover, it decomposes instantly, requiring the addition of a substance that can react with it. Unfortunately, this process can result in unintended chemical reactions that lead to a low yield of trifluoromethyl. To address the challenge of synthesizing trifluoromethyl from fluoroform, the research team developed a novel gas-liquid reactor with a zigzag-shaped channel and highly permeable non-porous membranes sandwiched between upper and lower channels. This configuration allowed for the swirling and mixing of superbase, a liquid utilized for dehydrogenation, and gaseous fluoroform within the reactor. By breaking fluoroform bubbles into smaller pieces to increase the contact area between gas and liquid, the team was able to effectively produce trifluoromethyl anion (CF3-). Unlike traditional approaches, they produced a fluoride intermediate effectively without requiring stabilizers or additives. The research team synthesized a fluorine-based compound by immediately adding a compound that will react with the fluoride anion intermediate. The entire process, which involved the generation of a fluorine anion intermediate from fluoroform took place within a second. The team maximized the formation of a trifluoromethyl anion, which is known to be short-lived, and rapidly facilitated the subsequent reaction before the intermediate decomposed. This method allowed for improved yield of fluoride-based compounds and introduced a robust technique for the synthesis of fluorine-based drugs. The research findings have significant implications for industrial applications in the economically efficient synthesis of fluoride compounds, making them more practical as well contributing significantly to studies on several unstable intermediates. The study was conducted with the support from the National Research Foundation of Korea.

05 Sep 2022

·www.prnewswire.com

Global $1.31 Bn Prostate Cancer Nuclear Medicine Diagnostics Market to 2028: Opportunities in the Growing Use of Radiopharmaceuticals

DUBLIN, Sept. 5, 2022 /PRNewswire/ -- The "Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, PET Product, and End User" report has been added to ResearchAndMarkets.com's offering. The global prostate cancer nuclear medicine diagnostics market is expected to grow from US$ 720.12 million in 2022 to US$ 1,315.66 million by 2028. It is estimated to grow at a CAGR of 10.6% from 2022 to 2028. Prostate cancer affects the prostate glands in males. Prostate cancer is common cancer following skin cancer in males. Common determinants responsible for prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and treat prostate cancer and helps radiologists conclude the stage of cancer. In terms of occurrence, prostate cancer (PCa) is the fourth most common cancer across the US. The rising incidences of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. This cancer is more likely to grow in older adults. Thus, the rising cases of prostate cancer offer substantial growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period. Based on type, the prostate cancer nuclear medicine diagnostics market is bifurcated into SPECT and PET. The PET segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR during the forecast period. A positron Emission Tomography (PET) scan is usually the most effective way to restage recurrent prostate cancer. After prostate cancer treatment, PET scanning may be used to determine the effectiveness of the treatment and is now commonly being used to detect biochemically recurrent prostate cancer for restaging. Rising research activities for developing novel imaging agents to improve prostate cancer detection and the development of novel imaging agents to improve prostate cancer detection are key factors driving the growth of nuclear medicine diagnostics. Researchers are conducting several studies to introduce new diagnostic agents for PET with higher efficiency than the existing agents. For instance, in March 2018, a study in The Journal of Nuclear Medicine demonstrated a novel PET agent named Copper-64 Chloride (64CuCl2) to detect prostate cancer. This new imaging agent exhibited a higher detection rate when compared with Fluorine-18-Choline (18F-choline). The adoption of PET as a diagnostic tool is significantly increasing, as it offers higher accuracy to that other diagnostic techniques. Accuracy in diagnosis has a direct impact on decision-making and treatment monitoring processes. Increasing demand for these diagnostic procedures is expected to fuel the growth of the prostate cancer nuclear medicine diagnostics market during the forecast period. Reimbursement policies is expected to further fuel the development of nuclear medicine diagnostics. Several programs such as Medicaid, Medicare, and the Health Insurance programs in the US are expected to create growth opportunities for the market players. For instance, the Centers for Medicare & Medicaid Services (CMS) covers PET services through National Coverage Determination (NCD) which includes tracers necessary for the diagnosis of prostate cancer. Therefore, due to the factors mentioned above, PET is expected to hold the largest market share. Key Market Dynamics Market Drivers Rising Prevalence of Prostate Cancer Surging Demand for Early and Precise Diagnosis of Prostate Cancer Market Restraints High Cost Related to the Prostate Cancer Diagnostics and Treatment Market Opportunities Growing Use of Radiopharmaceuticals in Prostate Cancer Future Trends Increasing Research Activities for Development of Innovative Imaging Agents Company Profiles Blue Earth Diagnostics Limited ImaginAB Curium Jubilant Radiopharma NCM-USA LLC ABX Advanced Biochemical Compounds GmbH Telix Pharmaceuticals Ltd. Novartis AG Theragonostics Lantheus Medical Imaging Inc. For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Diagnostic Reagents

27 Jun 2022

·www.globenewswire.com

Curium Announces the Submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency

PARIS, June 27, 2022 (GLOBE NEWSWIRE) -- Curium the world’s leading nuclear medicine company, today announced the submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency. The submission comes two months after completing its Phase III PYTHON trial of [18F]-DCFPyL and follows two US pivotal trials – OSPREY and CONDOR by Progenics Pharmaceuticals, Inc., a Lantheus company. In the U.S., [18F]-DCFPyL was approved by the FDA in May of 2021 and is commercially available as PYLARIFY® (Piflufolastat F 18 Injection) and sold by Lantheus. Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented: “The positive results of our Phase III PYTHON clinical trial conducted in Europe reinforce the diagnostic performance of [18F]-DCFPyL in the pivotal OSPREY and CONDOR clinical trials in multiple stages of prostate cancer disease, confirming our belief in [18F]-DCFPyL and the role it will play in helping Curium to redefine the experience of cancer.” Benoit Woessmer, PET Europe Chief Executive Officer at Curium added: “With the completion of the PYTHON clinical trial and the submission of our Marketing Authorization Application to the European Medicines Agency, Curium demonstrates its continued dedication and commitment to developing life-saving diagnostic solutions for cancer patients around the world. With our state-of-the-art PET radiopharmacy network – the largest in Europe, Curium will be ready to make the product available across Europe post approval in order to make an everyday impact on patients and people.” PYTHON Study The PYTHON Study (NCT04734184) was a Phase III, European, multicenter, prospective cross-over comparison trial, to evaluate and compare the detection rates, impact on patient management and safety proﬁles between [18F]-DCFPyL and [18F]-Fluorocholine (the current approved and established gold standard for PET/CT imaging of prostate cancer in Europe), in patients with first biochemical recurrence (BCR) after initial definitive therapy with curative intent. This study successfully met the primary endpoint. The details of the PYTHON study and the clinical results will be presented at the 35th Annual Congress of the European Association of Nuclear Medicine, October 15-19, 2022 in Barcelona, Spain. PYLARIFY® (piflufolastat F 18) Injection In the U.S., [18F]-DCFPyL was approved by the FDA in May of 2021 and is commercially available as PYLARIFY® (Piflufolastat F 18 Injection) and sold by Lantheus. U.S. Indication PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level Important Safety Information Contraindications None. Warnings and Precautions Risk of Image Misinterpretation Imaging interpretation errors can occur with PYLARIFY imaging. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. The performance of PYLARIFY for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by risk factors such as Gleason score and tumor stage. PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. Hypersensitivity Reactions Monitor patients for hypersensitivity reactions, particularly patients with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available. Radiation Risks Diagnostic radiopharmaceuticals, including PYLARIFY, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration. Adverse Reactions The most frequently reported adverse reactions were headaches, dysgeusia and fatigue, occurring at rate of ≤2% during clinical studies with PYLARIFY. In addition, a delayed hypersensitivity reaction was reported in one patient (0.2%) with a history of allergic reactions. Drug interactions Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of PYLARIFY in prostate cancer. The effect of these therapies on performance of PYLARIFY PET has not been established. To report suspected adverse reactions for PYLARIFY, call 1-800-362-2668 or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For important risk and use information about PYLARIFY Injection, please see Full Prescribing information. About Curium Curium is the world’s largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit curiumpharma.com.

License out/inDiagnostic Reagents

100 Deals associated with 18F-Fluorocholine

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V09	DB15887

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Liver Cancer	IT	-	03 Feb 2014
Prostatic Cancer	IT	-	03 Feb 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Localized Prostate Carcinoma	Discovery	FR	ABX advanced biochemical compounds GmbH	06 Mar 2019
Recurrent Prostate Carcinoma	Discovery	FR	ABX advanced biochemical compounds GmbH	06 Mar 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2024	Not Applicable	-	-	[18F]Fluorocholine	qhylphnzdn(bwuvuebpac) = jdtmvexqem brdrhcjnuc (jajnjvzslu, 2.5)	-	09 Jun 2024
SNMMI2022	Not Applicable	-	-	[18F]fluorocholine	geqmpakqix(gylkzgqiuc) = qltuquxoxl hvcvoaoebj (ykodoqghkn ) View more	-	08 Aug 2022
NCT02397408 (CTgov)	Phase 2	Prostatic Cancer	18	Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)+Carbon C 11 Choline+Fluorine F 18 Choline	vgzejgoblj(xzkhthhrkb) = rqkvadfcrz pnzbuemujk (hzmyyvkgmb, hncbpwioqh - mvtketjznm) View more	-	19 Nov 2020
SNMMI2019	Not Applicable	Hyperparathyroidism	-	18 F-FCH18F-FCHH (18F-FCH PET/CT)	(mfzaksztch) = nxqzbsllbv pwuivmcpqv (xhypcvfviq ) View more	-	21 May 2019
				18 F-FCH (99mTc-MIBI SPECT/CT)	(mfzaksztch) = lymawwzkzn pwuivmcpqv (xhypcvfviq ) View more
SNMMI2018	Not Applicable	Parathyroid Adenoma	-	18 F-Fluorocholine18F-FCHine (Dynamic 18F-FCH PET/CT)	jwsxxwzdlk(qtpvrntbyq) = statistically insignificant, indicating early dynamic imaging could suffice, without the need for a delayed image after 45 minutes vqjpztyowj (pifcqftuno ) View more	-	23 May 2018
				18 F-Fluorocholine18F-FCHline (Static 18F-FCH PET/CT)
SNMMI2017	Not Applicable	-	-	[18F]Fluorocholine	oqklxkmvkf(yplwkospbs) = < 1 µg/mL asdjcyyhll (konrflwfbd ) View more	-	24 May 2017
ASTRO2016	Not Applicable	Recurrent Prostate Carcinoma	-	Radical prostatectomy +/- radiation therapy (RT)	gztrdqtggu(epkghpkgtw) = jiatwepavo arezxmskdt (twmxmczyzi ) View more	-	01 Oct 2016
				18-F-Fluorocholine (RT)	gztrdqtggu(epkghpkgtw) = janmeopmey arezxmskdt (twmxmczyzi ) View more
ASTRO	Not Applicable	Brain metastases	-	[18F]-Fluorocholine (Lesions with viable tumor)	axkjgdbfyq(qvinyfrjsa) = trlatpoyzc aabtgqntas (runhpsiiad )	-	01 Oct 2016
				[18F]-Fluorocholine (Lesions with necrosis)	axkjgdbfyq(qvinyfrjsa) = soymryjmmw aabtgqntas (runhpsiiad )
NCT00928174 \| NCT00928252 (Pubmed \| J Nucl Med)	Phase 1/2	Castration-Resistant Prostatic Cancer	-	Chemotherapy	(wfaiixageo) = ysmggpqtzf wfytdecbog (zngojdfhyj )	-	01 Jul 2016
				<sup>18</sup>F-fluorocholine (Antiandrogens)	(wfaiixageo) = jcyzqojhue wfytdecbog (zngojdfhyj )
SNMMI2016	Not Applicable	-	-	[18F]Fluorocholine	gsqvqyyjkm(ofbipazwgc) = lower than 1 jivvsrmppo (dzydqdgthk ) View more	-	24 May 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis